CH620929A5 - - Google Patents
Download PDFInfo
- Publication number
- CH620929A5 CH620929A5 CH216575A CH216575A CH620929A5 CH 620929 A5 CH620929 A5 CH 620929A5 CH 216575 A CH216575 A CH 216575A CH 216575 A CH216575 A CH 216575A CH 620929 A5 CH620929 A5 CH 620929A5
- Authority
- CH
- Switzerland
- Prior art keywords
- antibiotic
- sodium
- sodium salt
- formyl
- acid
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 claims description 71
- 150000003839 salts Chemical class 0.000 claims description 53
- 239000000243 solution Substances 0.000 claims description 36
- -1 D-2-formyloxy-2-phenylacetamido Chemical group 0.000 claims description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 24
- 230000007062 hydrolysis Effects 0.000 claims description 21
- 238000006460 hydrolysis reaction Methods 0.000 claims description 21
- 159000000000 sodium salts Chemical class 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 150000007524 organic acids Chemical class 0.000 claims description 7
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 claims description 7
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 34
- 239000003814 drug Substances 0.000 description 22
- 229910000029 sodium carbonate Inorganic materials 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 241000588747 Klebsiella pneumoniae Species 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 241000588770 Proteus mirabilis Species 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- RRJHESVQVSRQEX-MRXJRLSOSA-N (6R)-7-[[(2R)-2-formyloxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound C(=O)O[C@@H](C(=O)NC1[C@@H]2N(C(=C(CS2)CSC2=NN=NN2C)C(=O)O)C1=O)C1=CC=CC=C1 RRJHESVQVSRQEX-MRXJRLSOSA-N 0.000 description 3
- 241000588772 Morganella morganii Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000588777 Providencia rettgeri Species 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XUTQHTOXGKVJPN-XCGJVMPOSA-N (6r)-7-amino-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)C(N)[C@H]2SC1 XUTQHTOXGKVJPN-XCGJVMPOSA-N 0.000 description 2
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000334216 Proteus sp. Species 0.000 description 2
- 241000588767 Proteus vulgaris Species 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000002814 agar dilution Methods 0.000 description 2
- 239000012984 antibiotic solution Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940082652 electrolytes and nutrients iv solution used in parenteral administration of fluids Drugs 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229940007042 proteus vulgaris Drugs 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- HJLCUPXTXWYUEZ-MDLDFJCZSA-N (2R)-2-hydroxy-N-[(6R)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]-2-phenylacetamide Chemical compound O[C@@H](C(=O)NC1[C@@H]2N(C=CCS2)C1=O)C1=CC=CC=C1 HJLCUPXTXWYUEZ-MDLDFJCZSA-N 0.000 description 1
- OLVCFLKTBJRLHI-ZUZSALNQSA-N (6R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound C([C@H](O)C1=CC=CC=C1)(=O)NC1[C@@H]2N(C(=C(CS2)CSC2=NN=NN2C)C(=O)O)C1=O OLVCFLKTBJRLHI-ZUZSALNQSA-N 0.000 description 1
- QITDACOZCQXYQY-BAFYGKSASA-N (6r)-7-amino-5-thia-1-azabicyclo[4.2.0]oct-2-en-8-one Chemical class S1CC=CN2C(=O)C(N)[C@H]21 QITDACOZCQXYQY-BAFYGKSASA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- NCLIGEZQAPUUQU-UHFFFAOYSA-N 2-silylacetamide Chemical compound NC(=O)C[SiH3] NCLIGEZQAPUUQU-UHFFFAOYSA-N 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000221671 Ophiostoma ulmi Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101000900567 Pisum sativum Disease resistance response protein Pi49 Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000589771 Ralstonia solanacearum Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- FZYXTYKAZUNHMF-UHFFFAOYSA-N formyl 2-hydroxy-2-phenylacetate Chemical compound C(=O)OC(C(O)C1=CC=CC=C1)=O FZYXTYKAZUNHMF-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical group O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- ICZOIXFFVKYXOM-QXPZFIFFSA-M sodium (6R)-7-[[(2R)-2-formyloxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C(=O)O[C@@H](C(=O)NC1[C@@H]2N(C(=C(CS2)CSC2=NN=NN2C)C(=O)[O-])C1=O)C1=CC=CC=C1.[Na+] ICZOIXFFVKYXOM-QXPZFIFFSA-M 0.000 description 1
- OJMNTWPPFNMOCJ-MDJBORCBSA-M sodium (6R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound O[C@@H](C(=O)NC1[C@@H]2N(C(=C(CS2)CSC2=NN=NN2C)C(=O)[O-])C1=O)C1=CC=CC=C1.[Na+] OJMNTWPPFNMOCJ-MDJBORCBSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US444622A US3928592A (en) | 1974-02-22 | 1974-02-22 | Antibiotic pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CH620929A5 true CH620929A5 (ja) | 1980-12-31 |
Family
ID=23765656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH216575A CH620929A5 (ja) | 1974-02-22 | 1975-02-21 |
Country Status (24)
Country | Link |
---|---|
US (1) | US3928592A (ja) |
JP (1) | JPS6119605B2 (ja) |
AR (1) | AR203895A1 (ja) |
AT (1) | AT356264B (ja) |
BE (1) | BE825653A (ja) |
CA (1) | CA1043261A (ja) |
CH (1) | CH620929A5 (ja) |
CS (1) | CS189689B2 (ja) |
DD (1) | DD117807A5 (ja) |
DE (1) | DE2506622C2 (ja) |
DK (1) | DK153919C (ja) |
ES (1) | ES434976A1 (ja) |
FR (1) | FR2261772B1 (ja) |
GB (1) | GB1493676A (ja) |
HU (1) | HU174129B (ja) |
IE (1) | IE40671B1 (ja) |
IL (1) | IL46650A (ja) |
NL (1) | NL179976C (ja) |
PH (1) | PH12058A (ja) |
PL (1) | PL109311B1 (ja) |
SE (1) | SE406153B (ja) |
SU (1) | SU659094A3 (ja) |
YU (1) | YU41875A (ja) |
ZA (1) | ZA75975B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4054738A (en) * | 1975-12-22 | 1977-10-18 | Eli Lilly And Company | Sodium cefamandole crystalline forms |
JPS5283956A (en) * | 1976-01-01 | 1977-07-13 | Lilly Co Eli | Antibiotic method and medical composition |
JPS5329936A (en) * | 1976-08-31 | 1978-03-20 | Takeda Chem Ind Ltd | Antibiotic composition |
JPS5711909A (en) * | 1980-06-23 | 1982-01-21 | Shionogi & Co Ltd | Stable freeze-dried preparation of beta-lactam |
CA2011365A1 (en) * | 1989-03-06 | 1990-09-06 | Eugene L. Inman | Diluent formulation for daptomycin |
JP4873207B2 (ja) * | 2001-02-26 | 2012-02-08 | 東レ・ファインケミカル株式会社 | 光学活性カルボン酸クロリドの精製方法 |
CN100554271C (zh) * | 2007-07-27 | 2009-10-28 | 苏州中联化学制药有限公司 | 抗菌素头孢孟多酯钠的合成方法 |
CN101880290B (zh) * | 2010-06-28 | 2012-03-07 | 海南新中正制药有限公司 | 头孢孟多酯钠的制备方法 |
WO2013057197A1 (en) * | 2011-10-20 | 2013-04-25 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Process for the formylation of cefamandole |
WO2013057196A1 (en) * | 2011-10-20 | 2013-04-25 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Process for the preparation of cefamandole nafate |
US9834567B1 (en) * | 2014-12-16 | 2017-12-05 | Tianjin University | Crystalline form of cefamandole nafate compound, preparation and preparing method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1767891C3 (de) * | 1968-06-28 | 1980-10-30 | Pfizer | Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat |
US3641021A (en) * | 1969-04-18 | 1972-02-08 | Lilly Co Eli | 3 7-(ring-substituted) cephalosporin compounds |
-
1974
- 1974-02-22 US US444622A patent/US3928592A/en not_active Expired - Lifetime
-
1975
- 1975-02-05 JP JP50015230A patent/JPS6119605B2/ja not_active Expired
- 1975-02-17 DE DE2506622A patent/DE2506622C2/de not_active Expired
- 1975-02-17 ZA ZA00750975A patent/ZA75975B/xx unknown
- 1975-02-18 BE BE1006466A patent/BE825653A/xx not_active IP Right Cessation
- 1975-02-18 FR FR7505039A patent/FR2261772B1/fr not_active Expired
- 1975-02-18 IL IL46650A patent/IL46650A/en unknown
- 1975-02-19 AR AR257697A patent/AR203895A1/es active
- 1975-02-20 NL NLAANVRAGE7502045,A patent/NL179976C/xx not_active IP Right Cessation
- 1975-02-20 GB GB7111/75A patent/GB1493676A/en not_active Expired
- 1975-02-20 PL PL1975178215A patent/PL109311B1/pl unknown
- 1975-02-20 AT AT128475A patent/AT356264B/de not_active IP Right Cessation
- 1975-02-20 DD DD184320A patent/DD117807A5/xx unknown
- 1975-02-21 CA CA220,537A patent/CA1043261A/en not_active Expired
- 1975-02-21 DK DK065575A patent/DK153919C/da not_active IP Right Cessation
- 1975-02-21 IE IE356/75A patent/IE40671B1/xx unknown
- 1975-02-21 CH CH216575A patent/CH620929A5/de not_active IP Right Cessation
- 1975-02-21 YU YU00418/75A patent/YU41875A/xx unknown
- 1975-02-21 PH PH16830A patent/PH12058A/en unknown
- 1975-02-21 SE SE7501985A patent/SE406153B/xx not_active IP Right Cessation
- 1975-02-21 CS CS751158A patent/CS189689B2/cs unknown
- 1975-02-21 HU HU75EI599A patent/HU174129B/hu unknown
- 1975-02-21 ES ES434976A patent/ES434976A1/es not_active Expired
- 1975-02-21 SU SU752109902A patent/SU659094A3/ru active
Also Published As
Publication number | Publication date |
---|---|
AT356264B (de) | 1980-04-25 |
IL46650A0 (en) | 1975-05-22 |
DD117807A5 (ja) | 1976-02-05 |
NL7502045A (nl) | 1975-08-26 |
AU7833975A (en) | 1976-08-19 |
IE40671L (en) | 1975-08-22 |
DE2506622A1 (de) | 1975-08-28 |
DE2506622C2 (de) | 1987-02-26 |
CA1043261A (en) | 1978-11-28 |
IE40671B1 (en) | 1979-07-18 |
SU659094A3 (ru) | 1979-04-25 |
BE825653A (fr) | 1975-08-18 |
CS189689B2 (en) | 1979-04-30 |
ZA75975B (en) | 1976-09-29 |
ATA128475A (de) | 1979-09-15 |
HU174129B (hu) | 1979-11-28 |
FR2261772A1 (ja) | 1975-09-19 |
JPS6119605B2 (ja) | 1986-05-17 |
FR2261772B1 (ja) | 1980-01-04 |
NL179976B (nl) | 1986-07-16 |
IL46650A (en) | 1977-10-31 |
PH12058A (en) | 1978-10-18 |
US3928592A (en) | 1975-12-23 |
GB1493676A (en) | 1977-11-30 |
YU41875A (en) | 1982-05-31 |
DK153919C (da) | 1989-02-06 |
SE406153B (sv) | 1979-01-29 |
PL109311B1 (en) | 1980-05-31 |
AR203895A1 (es) | 1975-10-31 |
NL179976C (nl) | 1986-12-16 |
SE7501985L (ja) | 1975-08-25 |
DK153919B (da) | 1988-09-26 |
DK65575A (ja) | 1975-10-20 |
ES434976A1 (es) | 1976-12-16 |
JPS50126817A (ja) | 1975-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2332878C2 (de) | Salze von Cephalosporinen mit Arginin und Lysin, ihre Herstellung und injizierbare pharmazeutische Zubereitungen | |
DE2506622C2 (de) | Antibiotisch wirksames Arzneimittel | |
EP0806955B1 (de) | Enrofloxacin-injektions- oder infusionslösungen | |
DE3019244C2 (ja) | ||
DE2739661C3 (de) | Jodderivat von Benzalkoniumchlorid und dieses enthaltendes Arzneimittel | |
DE3124592C2 (ja) | ||
DE3740588C2 (de) | Temperaturstabiles Breitband-Antibiotikum | |
DE68922127T2 (de) | Zinkceftiofurkomplexe. | |
DE69004921T2 (de) | Injizierbare Cephalosporinpräparate und ihre Anwendung. | |
DE2641388C3 (de) | 3',4'-Didesoxykanamycin B-N-methansulfonsäuren und deren Alkalimetallsalze sowie diese Verbindungen enthaltende pharmazeutische Präparate | |
DE2718730A1 (de) | Cephalosporin-antibiotika | |
DE2203653B2 (de) | 3-Carbamoyloxymethyl-7-(2-thienylacetamido)-3-cephem-4-carbonsäure und deren Salze, Verfahren zur Herstellung dieser Verbindungen und solche Verbindungen enthaltende Arzneimittel | |
DE2706156C3 (de) | N,N,N-Trimethylderivate amphoterer, antimykotischer Polyenantibiotika und Verfahren zu deren Herstellung | |
DE3104282C2 (ja) | ||
EP0183194B1 (de) | Menadioncholinbisulfit-Addukt und Verfahren zu dessen Herstellung | |
DE2001731B2 (de) | Erythromycinasparaginat, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Mittel | |
EP0152860B1 (de) | Verwendung von Cephemverbindungen zur Herstellung eines Arzneimittels für die Modulation des Immunsystems | |
DE2436959C2 (de) | Antibakterielle zusammensetzung mit einem gehalt an einer verbindung vom 3-fluor-d-alanin-typ und einer n-substituierten cycloserinverbindung | |
AT267061B (de) | Verfahren zur Herstellung eines neuen Erythromycinsalzes | |
DE2409431A1 (de) | Neue 6-aminopenicillansaeurederivate, verfahren zu deren herstellung und sie enthaltende mittel | |
KR800000604B1 (ko) | 비경구용 0-포밀세파만돌 나트륨염제제의 제조방법 | |
DE1593015C3 (de) | N.N'-Dimethyl-NJ'i'-di-detracyclinomethyl)-äthylendiamin und dessen Salze mit pharmakologisch unbedenklichen Mineral- und organischen Säuren sowie Verfahren zu deren Herstellung | |
DE971830C (de) | Verfahren zur Herstellung von stabilen wasserloeslichen Penicillin-Verbindungen | |
DE1543831C (de) | Verfahren zur Herstellung von Erythromy cinglutamat | |
DE2154027C3 (de) | alpha- (N-2-Pyrimidylf ormamidlno) benzylpenicillin sowie dessen nichttoxische Salze, Verfahren zu seiner Herstellung sowie es enthaltende Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |